Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer

Biomedicine and Pharmacotherapy

Volumn 58, Issue 9, 2004, Pages 531-535

  Toia, Masakazu ^a   Bandoa, Hiroko ^a   Chowb, Louis W C ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Breast cancer; Individualized treatment; Pathological response; Preoperative chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; PHENOTYPE; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SURVIVAL TIME; SYSTEMIC THERAPY; THEORETICAL STUDY; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; HUMANS; PREOPERATIVE CARE;

EID: 7044224875     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.12.016     Document Type: Short Survey

References (15)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
2. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
3. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001;79:103-7.
4. Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001;2:561-70.
5. Toi M, Bando H, Saji S. Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy. Med Sci Monit 2003;9:RA 90-5.
6. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-66.
7. Bear HD, Anderson S, Brown A, et al. The effect of tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003.
8. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
10. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;1:CD000486.
12. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer. Lessons from the laboratory. Nature Rev 2003;3:821-31.
13. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
14. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001;344:783-92.
15. Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003;98:1150-60.